| Basics |
Heron Therapeutics, Inc.
Heron Therapeutics Inc is a biotechnology company, developing products to address unmet medical needs. It is developing novel, patient-focused solutions that apply its science and technologies to already-approved pharmacological agents.
|
| IPO Date: |
January 23, 2014 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$288.35M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.39 | 3.09%
|
| Avg Daily Range (30 D): |
$0.07 | 3.55%
|
| Avg Daily Range (90 D): |
$0.07 | 3.57%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.23M |
| Avg Daily Volume (30 D): |
1.62M |
| Avg Daily Volume (90 D): |
1.58M |
| Trade Size |
| Avg Trade Size (Sh.): |
157 |
| Avg Trade Size (Sh.) (30 D): |
243 |
| Avg Trade Size (Sh.) (90 D): |
236 |
| Institutional Trades |
| Total Inst.Trades: |
3,407 |
| Avg Inst. Trade: |
$1.57M |
| Avg Inst. Trade (30 D): |
$1.35M |
| Avg Inst. Trade (90 D): |
$.96M |
| Avg Inst. Trade Volume: |
.12M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.03M |
| Avg Closing Trade (30 D): |
$.85M |
| Avg Closing Trade (90 D): |
$.7M |
| Avg Closing Volume: |
176.21K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-.05
|
$.02
|
$.02
|
|
Diluted EPS
|
$-.06
|
$.01
|
$.02
|
|
Revenue
|
$ 148.52M
|
$ 38.9M
|
$ 40.78M
|
|
Gross Profit
|
$ 109.86M
|
$ 30.45M
|
$ 30.55M
|
|
Net Income / Loss
|
$ -7.79M
|
$ 2.64M
|
$ 3.66M
|
|
Operating Income / Loss
|
$ -3.58M
|
$ 3.15M
|
$ 4.17M
|
|
Cost of Revenue
|
$ 38.66M
|
$ 8.46M
|
$ 10.23M
|
|
Net Cash Flow
|
$ -1.18M
|
$ -6.53M
|
$ .06M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Jan 13, 2014:
1:20
|
|
May 25, 2007:
1:4
|
|
